person · Reporting owner
Cox Christopher Nixon
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alto Neuroscience, Inc.ANRO · Entity 4755 | Director | May 12, 2026 | May 14, 2026 |
| High-Trend International GroupHTCO · Entity 7566 | Director | March 07, 2026 | March 16, 2026 |
| Newsmax Inc.NMAX · Entity 789 | Director | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alto Neuroscience, Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.63 · Expires 2036-05-11 | Direct | 10,958 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 10,958 · Balance 10,958 F2: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. F1: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.
F2: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.
High-Trend International Group
Report date March 07, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options on HTCO Class A Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2036-03-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-07 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
| Stock Options on HTCO Class A Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2036-12-10 | IndirectUnvested | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed |
| Stock Options on HTCO Class A Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2037-12-10 | IndirectUnvested | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed |
Newsmax Inc.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.31 · Expires 0036-05-20 | Direct | 23,940 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 23,940 · Balance 23,940 F1: The option was granted pursuant to the Issuer's 2025 Omnibus Equity Incentive Plan and a Stock Option Grant Notice and Option Agreement. The option shall become exercisable on the 12-month anniversary of the grant date, provided that the Reporting Person continues to provide services to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's 2025 Omnibus Equity Incentive Plan and a Stock Option Grant Notice and Option Agreement. The option shall become exercisable on the 12-month anniversary of the grant date, provided that the Reporting Person continues to provide services to the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 21, 2026 20:57 UTC | Newsmax Inc. NMAX · Entity 789 | GrantOption (Right to Buy) · Derivative | 23,940 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001628280-26-037364 · wk-form4_1779397037.xml · derivative · entry 1 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,940 Underlying: Class B Common Stock · 23,940 shares Expires 0036-05-20 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2025 Omnibus Equity Incentive Plan and a Stock Option Grant Notice and Option Agreement. The option shall become exercisable on the 12-month anniversary of the grant date, provided that the Reporting Person continues to provide services to the Issuer through such date. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:58 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 10,958 | $0.00 Strike: $24.63 | $0.00 |
DisclosureSEC source: 0002008212-26-000004 · wk-form4_1778792320.xml · derivative · entry 1 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,958 Underlying: Common Stock · 10,958 shares Expires 2036-05-11 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities. F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:47 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 7,189 | $11.82 Strike: $16.59 | $84,973.98 |
DisclosureSEC source: 0002008212-26-000002 · wk-form4_1767736023.xml · derivative · entry 1 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,189 Underlying: Common Stock · 7,189 shares Expires 2036-01-01 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $85,000. F1 · derivative.exercise_date: 1,797 shares underlying the option shall vest on March 31, 2026, 1,797 shares underlying the option shall vest on June 30, 2026, 1,798 shares underlying the option shall vest on September 30, 2026 and 1,797 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:16 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 15,287 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001999480-25-000040 · wk-form4_1747340192.xml · derivative · entry 1 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,287 Underlying: Common Stock · 15,287 shares Expires 2035-05-12 F2 · price: The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 28, 2025 Filed Apr 4, 2025 10:18 UTC | Newsmax Inc. NMAX · Entity 789 | GrantOption (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001213900-25-028778 · ownership.xml · derivative · entry 1 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-03-28 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2025 Omnibus Equity Incentive Plan and a Stock Option Grant Notice and Option Agreement. The option shall become exercisable on the 12-month anniversary of the grant date, provided that the Reporting Person continues to provide services to the Issuer through such date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:17 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 25,236 | $3.17 Strike: $4.38 | $79,998.12 |
DisclosureSEC source: 0001999480-25-000004 · wk-form4_1736198217.xml · derivative · entry 1 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,236 Underlying: Common Stock · 25,236 shares Expires 2035-01-01 F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $80,000. F1 · derivative.exercise_date: 6,309 shares underlying the option shall vest on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:39 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries C Preferred Stock · Derivative | 281,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002938 · form4-02072024_090202.xml · derivative · entry 4 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Lightswitch Capital Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 126,755 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and has no expiration date. F3 · derivative.exercise_date: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and has no expiration date. F3 · derivative.expiration_date: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and has no expiration date. F2 · ownership.nature: The shares are directly held by Lightswitch Capital Fund I, L.P. ("Lightswitch Capital"), of which Lightswitch Capital GP, LLC ("Lightswitch GP") is the sole general partner and exercises voting and investment power over these shares. The Reporting Person is the Chief Executive Officer of Lightswitch GP and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:39 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionSeries B Preferred Stock · Derivative | 1,250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002938 · form4-02072024_090202.xml · derivative · entry 3 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Lightswitch Capital Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 588,898 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F2 · ownership.nature: The shares are directly held by Lightswitch Capital Fund I, L.P. ("Lightswitch Capital"), of which Lightswitch Capital GP, LLC ("Lightswitch GP") is the sole general partner and exercises voting and investment power over these shares. The Reporting Person is the Chief Executive Officer of Lightswitch GP and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:39 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 126,755 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-002938 · form4-02072024_090202.xml · nonDerivative · entry 2 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Lightswitch Capital Fund I, L.P. Disclosed balance after: 715,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and has no expiration date. F2 · ownership.nature: The shares are directly held by Lightswitch Capital Fund I, L.P. ("Lightswitch Capital"), of which Lightswitch Capital GP, LLC ("Lightswitch GP") is the sole general partner and exercises voting and investment power over these shares. The Reporting Person is the Chief Executive Officer of Lightswitch GP and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:39 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | ConversionCommon Stock | 588,898 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-002938 · form4-02072024_090202.xml · nonDerivative · entry 1 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Lightswitch Capital Fund I, L.P. Disclosed balance after: 588,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date. F2 · ownership.nature: The shares are directly held by Lightswitch Capital Fund I, L.P. ("Lightswitch Capital"), of which Lightswitch Capital GP, LLC ("Lightswitch GP") is the sole general partner and exercises voting and investment power over these shares. The Reporting Person is the Chief Executive Officer of Lightswitch GP and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:42 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 4,623 | $11.88 Strike: $16.00 | $54,939.73 |
DisclosureSEC source: 0001415889-24-002558 · form4-02052024_090258.xml · derivative · entry 2 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,623 Underlying: Common Stock · 4,623 shares Expires 2034-01-31 F3 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $55,000. F2 · derivative.exercise_date: 840 shares underlying the option shall vest on March 31, 2024, and 1,261 shares underlying the option shall vest on each of June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:42 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantStock Option (right to buy) · Derivative | 30,574 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002558 · form4-02052024_090258.xml · derivative · entry 1 Cox Christopher Nixon · CIK 0002008212 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,574 Underlying: Common Stock · 30,574 shares Expires 2034-01-31 F1 · derivative.exercise_date: The shares underlying the option shall vest in 36 equal monthly installments commencing on March 1, 2024, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.